Abstract:The development of novel target therapies based on the use of RNA interference (RNAi) and antisense oligonucleotides (ASOs) is growing in an exponential way, challenging the chance for the treatment of the genetic diseases and cancer by hitting selectively targeted RNA in a sequence-dependent manner. Multiple opportunities are taking shape, able to remove defective protein by silencing RNA (e.g., Inclisiran targets mRNA of protein PCSK9, permitting a longer half-life of LDL receptors in heterozygous familial hypercholesteremia), by arresting mRNA translation (i.e., Fomivirsen that binds to UL123-RNA and blocks the translation into IE2 protein in CMV-retinitis), or by reactivating modified functional protein (e.g., Eteplirsen able to restore a functional shorter dystrophin by skipping the exon 51 in Duchenne muscular dystrophy) or a not very functional protein. In this last case, the use of ASOs permits modifying the expression of specific proteins by modulating splicing of specific pre-RNAs (e.g., Nusinersen acts on the splicing of exon 7 in SMN2 mRNA normally not expressed; it is used for spinal muscular atrophy) or by downregulation of transcript levels (e.g., Inotersen acts on the transthryretin mRNA to reduce its expression; it is prescribed for the treatment of hereditary transthyretin amyloidosis) in order to restore the biochemical/physiological condition and ameliorate quality of life. In the era of precision medicine, recently, an experimental splice-modulating antisense oligonucleotide, Milasen, was designed and used to treat an 8-year-old girl affected by a rare, fatal, progressive form of neurodegenerative disease leading to death during adolescence. In this review, we summarize the main transcriptional therapeutic drugs approved to date for the treatment of genetic diseases by principal regulatory government agencies and recent clinical trials aimed at the treatment of cancer. Their mechanism of action, chemical structure, administration, and biomedical performance are predominantly discussed.

Therapeutic development approaches to treat haploinsufficiency diseases: restoring protein levels

[Rare diseases: unraveling the biological bases to find future therapies]

From Challenge to Opportunity: How Shwachman-Diamond Syndrome Became a Promising Target for Therapy Development

Rare Opportunities: CRISPR/Cas-Based Therapy Development for Rare Genetic Diseases

Next-Generation Therapeutics for Rare Genetic Disorders

Huntington Disease: Linking Pathogenesis to the Development of Experimental Therapeutics

Therapy development in Huntington disease: From current strategies to emerging opportunities

Gene therapy strategies for rare monogenic disorders with nuclear or mitochondrial gene mutations

Preparing for Patient-Customized N-of-1 Antisense Oligonucleotide Therapy to Treat Rare Diseases

Developing DMD therapeutics: a review of the effectiveness of small molecules, stop-codon readthrough, dystrophin gene replacement, and exon-skipping therapies

An insight into allele-selective approaches to lowering mutant huntingtin protein for Huntington's disease treatment

Antisense oligonucleotides and their applications in rare neurological diseases

Between hope and reality: treatment of genetic diseases through nucleic acid-based drugs

Pharmacogenomics of Rare and Monogenic Disorders

Moving away from one disease at a time: Screening, trial design, and regulatory implications of novel platform technologies

Novel gene therapies for sickle cell disease, Duchenne muscular dystrophy, and hemophilia A

Improving access to gene therapy for rare diseases

Advances in Clinical Therapies for Huntington's Disease and the Promise of Multi-Targeted/Functional Drugs Based on Clinicaltrials.gov

Transcript-Targeted Therapy Based on RNA Interference and Antisense Oligonucleotides: Current Applications and Novel Molecular Targets

mRNA therapies: Pioneering a new era in rare genetic disease treatment

Mechanism-based approach in designing patient-specific combination therapies for nonsense mutation diseases